483341-15-7
Chemical Structure
A-286501
- CAS No.: 483341-15-7
- Formula:C11H14BrN5O2
- Molecular Weight:328.17
IUPAC Name: (1S,2R,3S,5R)-3-amino-5-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
InChIKey: FKFYQPGMXTXSTC-LWIVVEGESA-N
SMILES: O[C@H]1[C@@H](C[C@@H]([C@H]1O)N)N2C3=NC=NC(N)=C3C(Br)=C2
Biological Activity: A-286501 is an orally active adenosine kinase inhibitor with an IC50 of 0.47 nM (rat brain cytosol). A-286501 blocks the phosphorylation of adenosine to AMP and increases adenosine. A-286501 mediates non-opioid adenosine receptor-dependent antinociceptive and anti-inflammatory effects, reduces paw edema, myeloperoxidase activity, and tactile allodynia, and produces antinociceptive effects in acute, inflammatory, neuropathic, and hyperalgesic models. A-286501 can be used in research on inflammatory pain, neuropathic pain, and diabetic neuropathy[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A-286501 | A-286501 is an orally active adenosine kinase inhibitor with an IC50 of 0.47 nM (rat brain cytosol). A-286501 blocks the phosphorylation of adenosine to AMP and increases adenosine. A-286501 mediates non-opioid adenosine receptor-dependent antinociceptive and anti-inflammatory effects, reduces paw edema, myeloperoxidase activity, and tactile allodynia, and produces antinociceptive effects in acute, inflammatory, neuropathic, and hyperalgesic models. A-286501 can be used in research on inflammatory pain, neuropathic pain, and diabetic neuropathy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jarvis MF, et al. Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor. Pain. 2002 Mar;96(1-2):107-18. [Content Brief]
- [2]. McGaraughty S, et al. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Current topics in medicinal chemistry. 2005;5(1):43-58.
- [3]. McGaraughty S, et al. Purinergic control of neuropathic pain. Drug Development Research. 2006 Apr;67(4):376-88.
